Anika Therapeutics, Inc. (NASDAQ: ANIK) reported Q4 EPS of $0.51, $0.03 better than the analyst estimate of $0.48. Revenue for the quarter came in at $23.3 million versus the consensus estimate of $24.6 million.

For earnings history and earnings-related data on Anika Therapeutics, Inc. (ANIK) click here.